Diligence memo · auto-generated · as of July 3, 2026
Variant Pharmaceuticals, Inc.
Variant Pharmaceuticals, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Variant Pharmaceuticals, Inc. operates in Pharmaceuticals, based in WESTON.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Variant Pharmaceuticals, Inc. has raised $33M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2016-07-01.
Most recent recorded round closed around 2022-03-30.
Valuation (modeled)modeled
Provath models Variant Pharmaceuticals, Inc. at approximately $7.2M (range $881K–$20M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.06× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 4.3 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 3.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 75% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 13% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
19 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.